Month: September 2019

Macrophage Pharma Appoints Dr Anker Lundemose to the Board of Directors

Appointment widens industry leadership perspective, translational and commercial expertise 26 September 2019, Windsor, UK: Macrophage Pharma Limited (‘MPL’), a company focused on the discovery and development of next-generation immunomodulatory small molecules inducing transcriptional reprofiling of macrophages to combat cancer and other diseases, announced today that it has appointed Dr. Anker Lundemose as independent non-executive director. … Continue reading “Macrophage Pharma Appoints Dr Anker Lundemose to the Board of Directors”

Macrophage Pharma Appoints Dr Søren Bregenholt as Chief Executive Officer

Strategic and operational leadership expanded for progressing broad pipeline  03 September 2019, Windsor, UK: Macrophage Pharma Limited (‘MPL’), a company focused on the discovery and development of next-generation immunomodulatory small molecules inducing transcriptional reprofiling of macrophages to combat cancer and other diseases, announced today that it has appointed Dr Soren Bregenholt as Chief Executive … Continue reading “Macrophage Pharma Appoints Dr Søren Bregenholt as Chief Executive Officer”